Summit Therapeutics plc Aktie
Deine Einschätzung
Was spricht für und gegen Summit Therapeutics plc in den nächsten Jahren?
Pro
Kontra
Rendite von Summit Therapeutics plc im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Summit Therapeutics plc | - | - | - | - | - | - | - |
| Proteome Sciences | -15,63 % | 28,00 % | 146,15 % | -47,54 % | -44,83 % | -51,52 % | -31,91 % |
| Oxford BioMedica PLC | -0,69 % | 6,62 % | 4,32 % | 43,56 % | 42,16 % | 70,19 % | -17,44 % |
| Sareum Holdings plc | - | 0,76 % | -13,73 % | -56,29 % | -56,29 % | -84,56 % | - |
Kommentare
News
2 Stocks Up Over 600% in the Past 3 Years With More Room to Run
Those who had the foresight to invest in Summit Therapeutics (NASDAQ: SMMT) and Madrigal Pharmaceuticals (NASDAQ: MDGL) three years ago are sitting pretty right now. Both companies have soared over
Why a $27 Million Buy Signals New Confidence in Weatherford Stock
Summit Street Capital Management established a new position in Weatherford International (NASDAQ:WFRD), adding 398,661 shares valued at an estimated $27.3 million during the third quarter, according
Signet Jewelers Gains New $25 Million Institutional Backer — Is the Stock a Buy?
On November 14, New York City-based Summit Street Capital Management disclosed a new position in Signet Jewelers (NYSE:SIG), acquiring 264,054 shares valued at $25.3 million, according to its latest



